4CX Stock Overview
Cyxone AB (publ), a clinical stage biotech company, develops disease modifying therapies for autoimmune and autoinflammatory diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
Cyxone AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.0002 |
| 52 Week High | kr0.07 |
| 52 Week Low | kr0.0001 |
| Beta | 0.22 |
| 1 Month Change | -90.00% |
| 3 Month Change | -96.77% |
| 1 Year Change | -99.57% |
| 3 Year Change | -99.96% |
| 5 Year Change | -99.93% |
| Change since IPO | -99.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4CX | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -90.0% | -5.1% | -2.0% |
| 1Y | -99.6% | -21.1% | -0.3% |
Return vs Industry: 4CX underperformed the German Biotechs industry which returned -21.1% over the past year.
Return vs Market: 4CX underperformed the German Market which returned -0.3% over the past year.
Price Volatility
| 4CX volatility | |
|---|---|
| 4CX Average Weekly Movement | 2,343.3% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4CX's share price has been volatile over the past 3 months.
Volatility Over Time: 4CX's weekly volatility has decreased from 5242% to 2343% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 3 | Carl-Magnus Hogerkorp | www.cyxone.com |
Cyxone AB (publ), a clinical stage biotech company, develops disease modifying therapies for autoimmune and autoinflammatory diseases. Its product pipeline comprises Rabeximod, which is in phase II clinical development for the treatment of rheumatoid arthritis; and T20K for the treatment of multiple sclerosis and is in phase I trial. The company was founded in 2015 and is headquartered in Malmö, Sweden.
Cyxone AB (publ) Fundamentals Summary
| 4CX fundamental statistics | |
|---|---|
| Market cap | €1.66m |
| Earnings (TTM) | -€1.98m |
| Revenue (TTM) | €443.69k |
3.7x
P/S Ratio-0.8x
P/E RatioIs 4CX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4CX income statement (TTM) | |
|---|---|
| Revenue | kr5.15m |
| Cost of Revenue | kr0 |
| Gross Profit | kr5.15m |
| Other Expenses | kr28.14m |
| Earnings | -kr22.99m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 100.00% |
| Net Profit Margin | -446.56% |
| Debt/Equity Ratio | 0% |
How did 4CX perform over the long term?
See historical performance and comparison